Item 7.01 Regulation FD Disclosure.

Beginning on January 7, 2021, Krystal Biotech, Inc. (the "Company") plans to make a series of presentations to investors and other parties (the "Corporate Presentation") a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Corporate Presentation from time to time thereafter in connection with presentations to potential investors, industry analysts and others. The Corporate Presentation is available under the "Investors" section of the Company's website, located at www.krystalbio.com.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.




(d)  Exhibits.



Exhibit
  No.       Description

99.1          Corporate Presentation dated January 2021

104         Cover Page Interactive Data file (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses